Per- and polyfluorinated alkyl substances (PFAS) have been used abundantly since their inception in the twentieth century and have become a closely monitored class of compounds within environmental testing. This application note outlines a procedure for those seeking to become compliant with EPA Method 537.1. The data presented was generated using a Biotage® VacMaster™ vacuum manifold with a Large Volume Extraction (LVE) kit designed for PFAS work in conjunction with ISOLUTE® 101 SPE cartridges and a TurboVap® LV system. This note will demonstrate that the solution outlined is capable of generating data which exceeds the requirements outlined within the 537.1 method.
» Biotage® VacMaster™-20 Sample Processing Station
(with 16 mm rack), p/n 121-2016, fitted with polypropylene stopcocks (p/n 121-0009-PP)
» Biotage® VacMaster™ LVE Kit (PFAS) 1, 3, 6 mL SPE Cartridge (p/n 121-2190)
» ISOLUTE® 101 500 mg/6 mL SPE Cartridges, p/n 101-0050-C
» TurboVap® LV Automated Solvent Evaporation System, p/n 415000
» TurboVap® LV Multi Rack (48 Positions, 10–20 mm Tubes), p/n 414964
» USEPA Method 537.1 PDSL (linear) stocks, 1.2 mL, p/n EPA-537PDSL-R1
» USEPA Method 537 Internal Standard Mix, 1.2 mL, p/n EPA-537IS
» USEPA Method 537.1 Surrogate Mix, 1.2 mL, p/n EPA-537SS-R1
» PFAS Delay Cartridge, 5 μm, 50 x 2.1 mm, p/n 27854
» Raptor C18 LC Cartridge, 5 μm, 50 x 2.1 mm, p/n 9304552
» Ammonium Acetate, ACS Reagent Grade ≥ 97%, p/n 238074-25G
» Water, ACS Certified, HPLC Grade, p/n AH365-4
» Methanol, Burdick & Jackson™, LC-MS Grade, p/n LC230-4
» 15 mL Polypropylene Centrifuge Tubes with Caps, p/n 21008-670
» 250 mL Polypropylene Wide Mouth Bottles, p/n 414004-125
» Tris(hydroxymethyl)aminomethane, p/n 140505000
Listing of Target Analytes, Surrogate Standards, and Internal Standards.
|
Target Analyte |
Acronym |
CASRN |
|
Perfluorobutanesulfonic acid |
PFBS |
375-73-5 |
|
Perfluorohexanoic acid |
PFHxA |
307-24-4 |
|
Hexafluoropropylene oxide dimer acid |
HFPO-DA |
13252-13-6b |
|
Perfluorohexanesulfonic acid |
PFHxS |
355-46-4 |
|
4,8-dioxa-3H-perfluorononanoic acid |
ADONA |
919005-14-4e |
|
Perfluoroheptanoic acid |
PFHpA |
375-85-9 |
|
Perfluorooctanoic acid |
PFOA |
335-67-1 |
|
Perfluorooctanesulfonic acid |
PFOS |
1763-23-1 |
|
Perfluorononanoic acid |
PFNA |
375-95-1 |
|
9-chlorohexadecafluoro-3-oxanone-1-sulfonic acid |
9Cl-PF3ONS |
756426-58-1d |
|
Perfluorodecanoic acid |
PFDA |
335-76-2 |
|
Perfluoroundecanoic acid |
PFUnA |
2058-94-8 |
|
N-ethyl perfluorooctanesulfonamidoacetic acid |
NEtFOSAA |
2991-50-6 |
|
11-chloroeicosafluoro-3-oxaundecane-1-sulfonic acid |
11Cl-PF3OUdS |
763051-92-9c |
|
N-methyl perfluorooctanesulfonamidoacetic acid |
NMeFOSAA |
2355-31-9 |
|
Perfluorododecanoic acid |
PFDoA |
307-55-1 |
|
Perfluorotridecanoic acid |
PFTrDA |
72629-94-8 |
|
Perfluorotetradecanoic acid |
PFTA |
376-06-7 |
|
Surrogate Standard |
Acronym |
|---|---|
|
Perfluoro-n-[1,2-¹³C₂]hexanoic acid |
¹³C₂-PFHxA |
|
Tetrafluoro-2-heptafluoropropoxy-¹³C₃-propanoic acid |
¹³C₃-HFPO-DA |
|
Perfluoro-n-[1,2-¹³C₂]decanoic acid |
¹³C₂-PFDA |
|
N-deuterioethylperfluoro-1-octanesulfonamidoacetic acid |
d₅-N-EtFOSAA |
|
Internal Standard |
Acronym |
|---|---|
|
Perfluoro-[1,2-¹³C₂]octanoic acid |
¹³C₂-PFOA |
|
Sodium perfluoro-1-[1,2,3,4-¹³C₄]octanesulfonate |
¹³C₄-PFOS |
|
N-deuteriomethylperfluoro-1-octanesulfonamidoacetic acid |
d₃-N-MeFOSAA |
ISOLUTE® 101 500 mg/6 mL p/n 101-0050-C
Add 0.94 g of tris(hydroxymethyl)aminomethane and 660 μL of concentrated HCl to each 250 mL sample, check pH is 7 ± 0.5. Add surrogate standards.
Condition each cartridge with methanol (15 mL)
Equilibrate each cartridge with reagent water (18 mL + 3 mL)
Load sample (250 mL) at a flow rate of 15 mL/min
Rinse the cartridge with reagent water (sample bottle rinsate, 2 x 7.5 mL)
Dry the cartridge for 5 minutes using a vacuum of -10 to -15 in. Hg.
Elute the analytes with methanol (sample bottle rinsate 2 x 4 mL)
Evaporate to dryness and reconstitute in methanol/water (96/4, v/v, 990 μL). Add IS and mix prior to analysis.
TurboVap® LV Concentration Protocol.
|
Parameter |
Value |
|---|---|
|
Bath Temp |
60 °C |
|
Evaporation Mode |
Method (Ramp Gradient) |
|
Manifold Setup |
48 positions |
|
Rack Row Height |
120 mm* |
|
Step 1 |
2.5 L/min for 15 min |
|
Step 2 |
3.0 L/min for 15 min |
|
Step 3 |
3.5 L/min for 45 min |
*The nozzle position was adjusted such that it was as far to the right as possible to give the user a clear view of the vortex within the tube.
» CBM-20A Communications Controller
» DGU-20A5R Degassing Unit
» LC-30AD Solvent Delivery Unit
» SIL-30AC Autosampler
» CTO-30A Cartridge Over
» SPD-20A UV-Vis Detector
» Restek PFAS Delay Cartridge, 5 μm, 50 x 2.1 mm, p/n 27854
» Restek Raptor C18 LC Cartridge, 5 μm, 50 x 2.1 mm, p/n 9304552
A: 20 mM Ammonium Acetate in Water
B: Methanol
|
Time (min) |
%A |
%B |
|
0.01 |
95 |
5 |
|
0.10 |
45 |
55 |
|
4.50 |
1 |
99 |
|
4.95 |
1 |
99 |
|
5.00 |
95 |
5 |
|
6.75 |
Stop |
|
0.6 mL/min
10 μL
35 ˚C
Note: The PFAS conversion kit from SCIEX was installed and used for this testing with the exception of the included UHPLC cartridges.
35
8
-4500
350 ˚C
50
50
Negative
For a complete listing of MRM Transitions, see Appendix B
For the work being done here, a total of nine points were used in the calibration covering a range of 0.2-100 ppt in the sample. The lowest three points were below the calculated MRL. The curve was forced through zero as required by method 537.1 and achieved excellent linearity across the calibration range.
Figure 1. Calibration curves for PFOS and PFOA. Calibration curves for the remaining target analytes in Table 1 are shown in Appendix B.
Method 537.1 only requires that the first two eluting peaks on a single mid-level calibration standard have their peak asymmetry factors calculated and that the results of this calculation must fall within a range of 0.8-1.5. For the work done here, the scope of the investigation was broadened and six of the early eluting compounds were examined across all calibration levels. The results are given in Table below and shown graphically in Figure 2.
|
|
|
Concentration |
||||||||
|
|
RetentionTime (min.) |
0.2 ppt |
0.5 ppt |
1 ppt |
2 ppt |
4 ppt |
10 ppt |
20 ppt |
40 ppt |
100 ppt |
|
PFBS |
1.06 |
0.85 |
1.18 |
1.15 |
0.86 |
1.12 |
1.22 |
0.95 |
0.85 |
1.25 |
|
13C2-PFHxA (surr) |
1.21 |
1.13 |
1.10 |
0.96 |
1.14 |
0.93 |
1.01 |
1.23 |
1.03 |
1.07 |
|
PFHpA |
1.21 |
0.93 |
1.00 |
1.25 |
1.00 |
1.26 |
0.91 |
1.09 |
0.93 |
0.95 |
|
HFPO-DA |
1.27 |
1.04 |
1.02 |
1.39 |
1.05 |
1.37 |
1.47 |
1.14 |
1.49 |
1.00 |
|
13C3-HFPO-DA (surr) |
1.28 |
1.20 |
1.19 |
1.08 |
1.24 |
1.05 |
1.13 |
1.31 |
1.12 |
1.16 |
|
PFHxA |
1.45 |
0.86 |
0.87 |
1.16 |
0.95 |
1.15 |
1.24 |
1.01 |
1.21 |
0.87 |
Figure 2. Peak asymmetry factor with the range of acceptance shown in white.
Each of the first six eluting compounds across all calibration levels were able to meet and exceed the asymmetry factor requirements proving that the chromatographic conditions are acceptable.
A target MRL of 2 ng/L was selected and seven replicate laboratory fortified blanks (LFBs) were created and ran at that concentration. Table below lists the recoveries of the replicates, showing the averages and deviations for each compound along-side the calculated half-range for the prediction interval of results (HRPIR), the upper and lower bounds for the PIR, and the resulting DL calculations. It should be noted that the constant used to calculate the HRPIR and the DL was adjusted to accommodate the increased degrees of freedom for this experiment.
|
|
Conc. |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
Average |
Std. Dev. |
HRPIR |
Lower PIR |
Upper PIR |
DL |
|
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(ng/L) |
(%) |
(%) |
(ng/L) |
|
|
PFBS* |
1.77 |
1.69 |
1.97 |
1.82 |
1.87 |
2.27 |
1.99 |
2.09 |
1.96 |
0.19 |
0.70 |
62.9 |
133.1 |
0.57 |
|
PFHxA |
2.0 |
2.00 |
2.18 |
2.22 |
2.03 |
2.05 |
2.23 |
2.04 |
2.11 |
0.10 |
0.36 |
87.1 |
123.5 |
0.29 |
|
HFPO-DA |
2.0 |
1.82 |
2.03 |
2.24 |
2.05 |
2.05 |
2.09 |
1.85 |
2.02 |
0.14 |
0.53 |
74.5 |
127.4 |
0.43 |
|
PFHxS* |
1.89 |
1.86 |
2.08 |
1.99 |
1.70 |
1.98 |
1.84 |
2.12 |
1.94 |
0.15 |
0.54 |
69.9 |
123.9 |
0.44 |
|
ADONA* |
1.89 |
2.16 |
2.27 |
2.49 |
2.20 |
2.24 |
2.44 |
2.29 |
2.30 |
0.12 |
0.46 |
92.2 |
137.7 |
0.37 |
|
PFHpA |
2.0 |
1.91 |
2.26 |
2.41 |
2.12 |
2.01 |
2.22 |
2.20 |
2.16 |
0.17 |
0.62 |
77.2 |
138.9 |
0.50 |
|
PFOA |
2.0 |
1.92 |
2.22 |
2.22 |
2.12 |
2.17 |
2.19 |
1.98 |
2.12 |
0.12 |
0.44 |
83.7 |
127.9 |
0.36 |
|
PFOS* |
1.91 |
2.02 |
2.02 |
2.11 |
1.83 |
2.08 |
1.99 |
2.10 |
2.02 |
0.09 |
0.35 |
83.7 |
118.5 |
0.28 |
|
PFNA |
2.0 |
1.93 |
2.14 |
2.27 |
2.20 |
2.21 |
2.22 |
2.01 |
2.14 |
0.12 |
0.46 |
83.9 |
130.3 |
0.37 |
|
9Cl-PF3ONS* |
1.86 |
1.89 |
2.01 |
2.18 |
2.03 |
2.09 |
2.12 |
2.05 |
2.05 |
0.09 |
0.35 |
85.5 |
120.0 |
0.28 |
|
PFDA |
2.0 |
1.80 |
2.07 |
2.31 |
2.14 |
2.05 |
2.10 |
1.90 |
2.05 |
0.16 |
0.61 |
72.1 |
133.2 |
0.49 |
|
PFUnA |
2.0 |
1.91 |
1.99 |
2.18 |
1.84 |
1.98 |
2.06 |
1.92 |
1.98 |
0.11 |
0.41 |
78.8 |
119.7 |
0.33 |
|
NEtFOSAA |
2.0 |
1.87 |
2.03 |
1.95 |
1.97 |
1.93 |
2.23 |
1.58 |
1.94 |
0.19 |
0.72 |
61.1 |
132.6 |
0.58 |
|
11Cl-PF3OUdS* |
1.88 |
1.86 |
1.82 |
1.94 |
1.75 |
2.03 |
1.92 |
1.96 |
1.89 |
0.09 |
0.35 |
77.2 |
112.3 |
0.28 |
|
NMeFOSAA |
2.0 |
1.75 |
2.02 |
1.90 |
1.76 |
2.03 |
1.97 |
1.57 |
1.86 |
0.17 |
0.64 |
60.8 |
124.9 |
0.52 |
|
PFDoA |
2.0 |
2.17 |
1.94 |
2.11 |
1.92 |
2.01 |
2.13 |
1.81 |
2.01 |
0.13 |
0.49 |
76.1 |
125.1 |
0.40 |
|
PFTrDA |
2.0 |
1.70 |
1.89 |
1.95 |
1.67 |
1.85 |
1.87 |
1.67 |
1.80 |
0.12 |
0.44 |
68.2 |
111.7 |
0.35 |
|
PFTA |
2.0 |
1.75 |
1.94 |
1.98 |
1.69 |
1.67 |
1.97 |
1.63 |
1.80 |
0.15 |
0.56 |
62.2 |
118.2 |
0.45 |
*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
Figure 3. Upper and Lower calculated PIR limits with the range of acceptance shown in white. Those compounds with an asterisk were used in salt form.
Based on the data obtained, the calculated Upper and Lower PIR were all well within the specified boundaries and the MRL concentrations given in Table 5 are all deemed acceptable. The DL was calculated from this data set and is found to be lower than the DL given in Table 5 of EPA Method 537.1.
An investigation into the background of the complete process was done in three steps. The first step was to run blank injections of a mixture of 96% methanol/4% water on the analytical system (system blank). The second step was to load centrifuge tubes containing a similar volume of methanol as would result from the extraction process onto the evaporation system, allowing them to concentrate to dryness, be reconstituted, and then run on the analytical system (evaporation blank). The third and final step was to create a full Laboratory Reagent Blank (LRB), extract and concentrate it, reconstitute it, and run it on the analytical system. By separating the process into three separate steps it becomes easier to determine what, if any, contribution to the overall background each of the steps has. The result of these tests are shown in Table below and selected data are shown graphically in Figures 4 and 5.
|
|
TurboVap® LV |
Laboratory Reagent Blank |
||||||||||||
|
Replicate |
1 |
2 |
3 |
4 |
5 |
6 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
|
PFBS* |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
0.011 |
0.020 |
0.019 |
0.042 |
0.033 |
0.017 |
0.021 |
0.011 |
|
PFHxA |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
0.084 |
0.082 |
0.083 |
0.089 |
0.094 |
0.139 |
0.087 |
0.090 |
|
HFPO-DA |
N.D. |
N.D. |
N.D. |
0.002 |
0.006 |
N.D. |
0.032 |
0.024 |
0.031 |
0.028 |
0.038 |
0.032 |
0.026 |
0.036 |
|
PFHxS* |
N.D. |
N.D. |
N.D. |
N.D. |
0.061 |
N.D. |
0.034 |
0.019 |
0.042 |
0.031 |
0.032 |
0.050 |
0.030 |
0.034 |
|
ADONA* |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
0.004 |
0.032 |
0.031 |
0.034 |
0.031 |
0.031 |
0.032 |
0.028 |
0.040 |
|
PFHpA |
N.D. |
0.030 |
0.012 |
0.031 |
0.024 |
0.012 |
0.050 |
0.069 |
0.064 |
0.067 |
0.054 |
0.065 |
0.057 |
0.068 |
|
PFOA |
0.073 |
0.069 |
0.050 |
0.071 |
0.071 |
0.063 |
0.082 |
0.083 |
0.085 |
0.076 |
0.081 |
0.088 |
0.086 |
0.102 |
|
PFOS* |
0.143 |
0.143 |
0.115 |
0.145 |
0.130 |
0.137 |
0.086 |
0.091 |
0.086 |
0.091 |
0.097 |
0.110 |
0.097 |
0.095 |
|
PFNA |
N.D. |
0.015 |
0.013 |
0.005 |
0.014 |
N.D. |
0.030 |
0.039 |
0.032 |
0.038 |
0.052 |
0.038 |
0.034 |
0.037 |
|
9Cl-PF3ONS* |
N.D. |
0.004 |
N.D. |
0.005 |
0.002 |
0.003 |
0.029 |
0.033 |
0.029 |
0.031 |
0.037 |
0.035 |
0.033 |
0.032 |
|
PFDA |
N.D. |
N.D. |
N.D. |
0.005 |
0.013 |
N.D. |
0.046 |
0.050 |
0.045 |
0.045 |
0.048 |
0.051 |
0.037 |
0.097 |
|
PFUnA |
N.D. |
N.D. |
N.D. |
0.026 |
N.D. |
0.012 |
0.032 |
0.025 |
0.027 |
0.027 |
0.025 |
0.034 |
0.029 |
0.035 |
|
NEtFOSAA |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
0.026 |
0.025 |
0.025 |
0.020 |
0.029 |
0.032 |
0.021 |
0.032 |
|
11Cl-PF3OUdS* |
N.D. |
0.006 |
N.D. |
N.D. |
0.003 |
N.D. |
0.028 |
0.029 |
0.028 |
0.030 |
0.039 |
0.033 |
0.030 |
0.030 |
|
NMeFOSAA |
N.D. |
N.D. |
N.D. |
N.D. |
N.D. |
0.013 |
0.048 |
0.044 |
0.044 |
0.041 |
0.044 |
0.047 |
0.039 |
0.034 |
|
PFDoA |
N.D. |
0.004 |
N.D. |
0.007 |
0.008 |
0.007 |
0.022 |
0.031 |
0.027 |
0.028 |
0.025 |
0.025 |
0.027 |
0.029 |
|
PFTrDA |
N.D. |
0.003 |
N.D. |
0.013 |
0.014 |
N.D. |
0.022 |
0.028 |
0.025 |
0.026 |
0.023 |
0.021 |
0.018 |
0.025 |
|
PFTA |
N.D. |
N.D. |
N.D. |
N.D. |
0.004 |
N.D. |
0.020 |
0.019 |
0.020 |
0.020 |
0.020 |
0.018 |
0.014 |
0.024 |
*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
NOTE: Where “N.D.” is indicative of the inability of the target peak to be separated from the system background.
Figure 4. Contribution of the TurboVap® LV to the PFAS Background. Those compounds with an asterisk were used in salt form.
Figure 5. PFAS Background for full LRB. Those compounds with an asterisk were used in salt form.
For those results which were generated using only the analytical system, all target analytes were N.D. (unable to be separated from the noise in the baseline) and so were not listed out in the previous tables.
When examining the data resulting for both the TurboVap® LV and the full LRB (which includes the Biotage® VacMaster™ manifold, Large Volume Loading Kit, and the ISOLUTE® 101 cartridges as well as the TurboVap® LV) there are clear indications of the presence of a PFAS background. However, even at the highest concentrations detected, all levels are much lower than the 1/3 MRL limit specified within EPA Method 537.1 indicating that the background is acceptable and will not interfere with future sample runs.
To determine the precision and accuracy of the sample preparation process, eight LFB samples were prepared at concentrations of 20 ppt. The data is shown in Table below and illustrated in Figures 6 and 7.
The results show that the average recovery for each target analyte was within 15% of the nominal value; falling well within the criteria of ± 30% stated within Method 537.1. Additionally, the relative standard deviation (RSD) for each analyte fell under 11% on average; again being much less than the 20% requirement set forth within the method.
|
Replicate |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
Average |
Std. Dev. |
RSD |
|
|
(%) |
(%) |
(%) |
(%) |
(%) |
(%) |
(%) |
(%) |
(%) |
(%) |
(%) |
|
PFBS* |
94.5 |
108.1 |
107.5 |
114.8 |
127.2 |
119.8 |
113.1 |
120.6 |
110.5 |
11.9 |
10.8 |
|
PFHxA |
92.3 |
110.1 |
107.2 |
111.4 |
112.4 |
101.7 |
106.5 |
118.4 |
106.7 |
8.3 |
7.8 |
|
HFPO-DA |
91.4 |
106.6 |
106.2 |
109.2 |
109.0 |
100.6 |
102.7 |
114.6 |
104.5 |
7.4 |
7.1 |
|
PFHxS* |
94.3 |
107.3 |
104.0 |
105.9 |
112.2 |
108.0 |
105.4 |
110.2 |
104.7 |
6.6 |
6.3 |
|
ADONA* |
95.5 |
118.2 |
112.6 |
119.4 |
120.1 |
103.3 |
111.9 |
115.9 |
113.2 |
10.3 |
9.1 |
|
PFHpA |
96.4 |
107.0 |
108.3 |
109.2 |
113.3 |
97.0 |
109.7 |
117.5 |
106.9 |
6.3 |
5.9 |
|
PFOA |
95.0 |
109.4 |
110.9 |
116.5 |
115.8 |
104.3 |
106.9 |
118.2 |
109.5 |
8.7 |
7.9 |
|
PFOS* |
93.2 |
112.5 |
106.5 |
117.4 |
112.4 |
108.5 |
115.3 |
117.2 |
108.4 |
9.3 |
8.6 |
|
PFNA |
93.9 |
110.5 |
106.1 |
110.2 |
112.6 |
97.0 |
106.5 |
115.6 |
106.7 |
7.5 |
7.0 |
|
9Cl-PF3ONS* |
88.5 |
103.3 |
104.5 |
118.1 |
113.1 |
102.0 |
106.7 |
112.6 |
105.5 |
11.3 |
10.7 |
|
PFDA |
98.0 |
107.6 |
110.0 |
113.6 |
115.0 |
99.7 |
108.1 |
109.4 |
108.8 |
6.7 |
6.2 |
|
PFUdA |
90.9 |
105.6 |
103.3 |
105.9 |
109.3 |
93.3 |
98.5 |
113.7 |
103.0 |
7.1 |
6.9 |
|
NEtFOSAA |
90.3 |
101.9 |
101.1 |
108.9 |
104.7 |
103.6 |
111.1 |
110.9 |
101.4 |
6.9 |
6.8 |
|
11Cl-PF3OUdS* |
90.2 |
102.4 |
100.9 |
107.8 |
109.1 |
99.4 |
108.4 |
109.9 |
102.1 |
7.5 |
7.3 |
|
NMeFOSAA |
92.0 |
102.0 |
103.3 |
108.0 |
107.3 |
106.5 |
107.5 |
112.7 |
102.5 |
6.4 |
6.2 |
|
PFDoA |
86.4 |
103.2 |
96.6 |
109.7 |
106.1 |
90.0 |
98.2 |
109.0 |
100.4 |
9.2 |
9.1 |
|
PFTrDA |
84.4 |
100.5 |
100.4 |
103.1 |
103.2 |
94.0 |
98.5 |
110.6 |
98.3 |
7.9 |
8.0 |
|
PFTA |
86.0 |
99.2 |
99.9 |
103.2 |
107.4 |
90.9 |
97.2 |
104.5 |
99.1 |
8.0 |
8.1 |
*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
Figure 6. Initial Demonstration of Accuracy with range of acceptance shown in white (20 ng/L, n=8). Those compounds with an asterisk were used in salt form.
Figure 7. Initial Demonstration of Precision with range of acceptance shown in white (20 ng/L, n=8). Those compounds with an asterisk were used in salt form.
To simulate an influent sample, eight LFB samples were created with concentrations which were much higher that the calibration curve. These samples were split into two groups of four. The first group of four samples were extracted and, immediately following them, a LRB was extracted. For the second group, again four samples were extracted followed by a set of four LRB samples however, between the two extractions the cleaning procedure given in Appendix A was run three times. The sets of LFB and LRB samples were analyzed and the data for the LRB runs is given in Table 8 and illustrated in Figure 8.
The graph shown in Figure 8 indicates that without a cleaning procedure between influent and effluent sample extractions, carryover should be expected for some of the PFAS compounds contained within the test. Additionally, while the cleaning procedure did reduce the background to a point below the 1/3 MRL limit on average for all compounds, there is one instance where the compound NEtFOSAA was found to be above the limit. This indicates that further cleaning should be done in the future for influent samples of this concentration.
Figure 8. Results of carryover study following eight, 400 ng/L LFB samples; Four LRB samples extracted without cleaning procedure and four with the cleaning procedure in Appendix A. Those compounds with an asterisk were used in salt form.
Results of carryover study following eight, 400 ng/L LFB samples; Four LRB samples extracted without cleaning procedure and four with the cleaning procedure in Appendix A.
|
|
Not Cleaned |
Cleaned |
||||||||
|
Replicate |
1 (ppt) |
2 (ppt) |
3 (ppt) |
4 (ppt) |
Average (ppt) |
1 (ppt) |
2 (ppt) |
3 (ppt) |
4 (ppt) |
Average (ppt) |
|
PFBS* |
0.038 |
0.079 |
0.033 |
0.082 |
0.058 |
0.061 |
0.133 |
0.033 |
0.064 |
0.073 |
|
HFPO-DA |
0.018 |
0.039 |
0.022 |
0.010 |
0.022 |
0.007 |
0.012 |
0.027 |
0.019 |
0.016 |
|
ADONA* |
0.023 |
0.020 |
0.020 |
0.010 |
0.018 |
0.011 |
0.011 |
0.014 |
0.011 |
0.012 |
|
PFOA |
0.064 |
0.091 |
0.067 |
0.065 |
0.071 |
0.061 |
0.072 |
0.074 |
0.064 |
0.068 |
|
PFNA |
0.063 |
0.070 |
0.029 |
0.061 |
0.056 |
0.018 |
0.027 |
0.036 |
0.025 |
0.027 |
|
PFDA |
0.199 |
0.096 |
0.050 |
0.175 |
0.130 |
0.058 |
0.032 |
0.040 |
0.045 |
0.044 |
|
NEtFOSAA |
2.949 |
1.997 |
1.216 |
1.544 |
1.926 |
0.410 |
0.740 |
0.563 |
0.556 |
0.567 |
|
NMeFOSAA |
1.544 |
0.996 |
0.518 |
0.704 |
0.940 |
0.298 |
0.384 |
0.253 |
0.310 |
0.311 |
|
PFTrDA |
0.625 |
0.335 |
0.172 |
0.331 |
0.366 |
0.053 |
0.087 |
0.080 |
0.067 |
0.072 |
|
PFTA |
0.506 |
0.280 |
0.158 |
0.291 |
0.309 |
0.051 |
0.074 |
0.086 |
0.068 |
0.070 |
*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
With the scrutiny being given to the presence of PFAS compounds in the environment, it is essential to find reliable products which can meet the requirements of EPA Method
537.1. This application note has shown that the Biotage® VacMaster™ vacuum manifold with accessories, ISOLUTE® 101 SPE cartridges and the TurboVap® LV can be used to easily meet and exceed the demands of the method.
|
Part Number |
Description |
Quantity |
|
121-2016 |
Biotage® VacMaster™-20 Sample Processing Station (with 16 mm rack) |
1 |
|
121-2190 |
Biotage® VacMaster™ LVE Kit (PFAS) for 1, 3, 6 mL SPE Cartridge |
1 |
|
121-0009-PP |
Biotage® VacMaster™ PP (PFAS) Stopcock |
10 |
|
120-1111 |
ISOLUTE® Cartridge Adapters (PFAS) 1, 3, 6 mL Cartridges |
10 |
|
101-0050-C |
ISOLUTE® 101 SPE Cartridges, 500 mg/6 mL |
30 |
|
415000 |
TurboVap® LV Automated Solvent Evaporation System |
1 |
|
414964 |
TurboVap® LV Multi Rack (48 Positions, 10–20 mm Tubes) |
1 |
For the best results, it is recommended that this procedure be completed before the use of the Biotage® VacMaster™ each day and at the end of each extraction prior to proceeding with the next set of samples.
Note: In situations where the previous sample was highly concentrated, the above cleaning procedure may need to be repeated multiple times. If there is concern regarding potential carryover contamination regardless of the cleaning procedure, a laboratory reagent blank should be run in that position to ensure its cleanliness.
|
|
Q1 Mass (Da) |
Q3 Mass (Da) |
Time (Min) |
ID |
DP (Volts) |
CE (Volts) |
CXP (Volts) |
|
1 |
314.900 |
269.900 |
1.14 |
MPFHxA |
-40.000 |
-14.000 |
-11.000 |
|
2 |
314.900 |
119.000 |
1.14 |
MPFHxA |
-40.000 |
-26.000 |
-7.000 |
|
3 |
514.900 |
429.900 |
2.33 |
MPFDA |
-60.000 |
-16.000 |
-19.000 |
|
4 |
514.900 |
219.500 |
2.33 |
MPFDA |
-60.000 |
-26.000 |
-11.000 |
|
5 |
588.900 |
419.000 |
2.64 |
d5-N-EtFOSAA |
-165.000 |
-28.000 |
-17.000 |
|
6 |
588.900 |
531.000 |
2.64 |
d5-N-EtFOSAA |
-165.000 |
-28.000 |
-17.000 |
|
7 |
256.900 |
168.900 |
1.19 |
M3HFPO-DA |
-90.000 |
-10.000 |
-9.000 |
|
8 |
256.000 |
184.900 |
1.19 |
M3HFPO-DA |
-90.000 |
-24.000 |
-11.000 |
|
9 |
414.900 |
370.000 |
1.64 |
IS-M2PFOA |
-55.000 |
-14.000 |
-5.000 |
|
10 |
414.900 |
169.500 |
1.64 |
IS-M2PFOA |
-55.000 |
-26.000 |
-9.000 |
|
11 |
572.900 |
419.000 |
2.48 |
IS-d3-N-MeFOSA |
-120.000 |
-28.000 |
-7.000 |
|
12 |
572.900 |
483.000 |
2.48 |
IS-d3-N-MeFOSA |
-120.000 |
-22.000 |
-7.000 |
|
13 |
502.300 |
80.000 |
1.98 |
IS-MPFOS |
-90.000 |
-110.000 |
-11.000 |
|
14 |
502.300 |
98.800 |
1.98 |
IS-MPFOS |
-90.000 |
-98.000 |
-9.000 |
|
15 |
312.900 |
268.900 |
1.13 |
PFHxA |
-45.000 |
-14.000 |
-11.000 |
|
16 |
312.900 |
118.900 |
1.13 |
PFHxA |
-45.000 |
-28.000 |
-7.000 |
|
17 |
362.900 |
318.900 |
1.35 |
PFHpA |
-55.000 |
-14.000 |
-7.000 |
|
18 |
362.900 |
168.900 |
1.35 |
PFHpA |
-55.000 |
-24.000 |
-9.000 |
|
19 |
412.900 |
369.000 |
1.64 |
PFOA |
-45.000 |
-16.000 |
-5.000 |
|
20 |
412.900 |
168.900 |
1.64 |
PFOA |
-45.000 |
-24.000 |
-9.000 |
|
21 |
462.900 |
419.000 |
1.98 |
PFNA |
-55.000 |
-16.000 |
-9.000 |
|
22 |
462.900 |
218.900 |
1.98 |
PFNA |
-55.000 |
-24.000 |
-3.000 |
|
23 |
512.900 |
469.000 |
2.33 |
PFDA |
-55.000 |
-16.000 |
-9.000 |
|
24 |
512.900 |
218.900 |
2.33 |
PFDA |
-55.000 |
-26.000 |
-7.000 |
|
25 |
562.900 |
519.000 |
2.65 |
PFUdA |
-65.000 |
-18.000 |
-9.000 |
|
26 |
562.900 |
268.900 |
2.65 |
PFUdA |
-65.000 |
-26.000 |
-7.000 |
|
27 |
612.900 |
569.000 |
2.95 |
PFDoA |
-70.000 |
-18.000 |
-11.000 |
|
28 |
612.900 |
318.900 |
2.95 |
PFDoA |
-70.000 |
-28.000 |
-5.000 |
|
29 |
662.800 |
619.000 |
3.20 |
PFTrDA |
-65.000 |
-20.000 |
-7.000 |
|
30 |
662.800 |
169.000 |
3.20 |
PFTrDA |
-65.000 |
-36.000 |
-7.000 |
|
31 |
712.800 |
669.000 |
3.43 |
PFTeDA |
-75.000 |
-20.000 |
-7.000 |
|
32 |
712.800 |
169.000 |
3.43 |
PFTeDA |
-75.000 |
-36.000 |
-14.000 |
|
33 |
569.900 |
419.000 |
2.47 |
N-MeFOSAA |
-90.000 |
-28.000 |
-7.000 |
|
34 |
569.900 |
483.000 |
2.47 |
N-MeFOSAA |
-90.000 |
-22.000 |
-17.000 |
|
35 |
583.900 |
419.000 |
2.63 |
N-EtFOSAA |
-90.000 |
-28.000 |
-7.000 |
|
36 |
583.900 |
526.000 |
2.63 |
N-EtFOSAA |
-90.000 |
-28.000 |
-7.000 |
|
37 |
284.900 |
168.900 |
1.18 |
HFPO-DA |
-80.000 |
-10.000 |
-7.000 |
|
38 |
284.900 |
184.900 |
1.18 |
HFPO-DA |
-80.000 |
-22.000 |
-9.000 |
|
39 |
298.300 |
79.900 |
1.00 |
L-PFBS |
-75.000 |
-62.000 |
-11.000 |
|
40 |
298.300 |
98.900 |
1.00 |
L-PFBS |
-75.000 |
-36.000 |
-5.000 |
|
41 |
398.400 |
80.000 |
1.36 |
L-PFHxS |
-110.000 |
-86.000 |
-11.000 |
|
42 |
398.400 |
99.000 |
1.36 |
L-PFHxS |
-110.000 |
-42.000 |
-5.000 |
|
43 |
498.600 |
79.900 |
1.98 |
L-PFOS |
-255.000 |
-110.000 |
-11.000 |
|
44 |
498.800 |
99.000 |
1.98 |
L-PFOS |
-255.000 |
-94.000 |
-5.000 |
|
45 |
376.900 |
250.900 |
1.38 |
ADONA |
-45.000 |
-16.000 |
-9.000 |
|
46 |
376.900 |
64.900 |
1.38 |
ADONA |
-45.000 |
-36.000 |
-7.000 |
|
47 |
530.800 |
350.900 |
2.16 |
9Cl-PF3ONS |
-90.000 |
-36.000 |
-7.000 |
|
48 |
530.800 |
83.000 |
2.16 |
9Cl-PF3ONS |
-90.000 |
-68.000 |
-7.000 |
|
49 |
630.800 |
450.900 |
2.79 |
11Cl-PF3OUdS |
-125.000 |
-42.000 |
-13.000 |
|
50 |
630.800 |
82.900 |
2.79 |
11Cl-PF3OUdS |
-125.000 |
-88.000 |
-13.000 |
Figure 9. Calibration curves for the target analytes in Table 1, covering a concentration range of 0.2-100 ppt.
Literature number: AN958